# A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)

> **NCT00261508** · PHASE3 · COMPLETED · sponsor: **Janssen-Ortho Inc., Canada** · enrollment: 80 (actual)

## Conditions studied

- DCild Development Disorders, Pervasive
- Autistic Disorder
- Developmental Disabilities
- Asperger Syndrome
- Rett Syndrome

## Interventions

- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00261508
- **Lead sponsor:** Janssen-Ortho Inc., Canada
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-08
- **Primary completion:** —
- **Final completion:** 2001-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00261508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00261508, "A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00261508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*